ATE535252T1 - Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit - Google Patents

Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit

Info

Publication number: ATE535252T1
Authority: AT; Austria
Prior art keywords: methods; disease; preventing; immunogenic fragment; peptide conjugate
Prior art date: 2005-05-05

Application number

AT06751930T

Other languages

English (en)

Inventor

Victor GARSKY

Joseph JOYCE

Paul Keller

Gene Kinney

Xiaoping Liang

John SHIVER

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-05

Filing date

2006-05-01

Publication date

2011-12-15

2006-05-01 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2011-12-15 Application granted granted Critical

2011-12-15 Publication of ATE535252T1 publication Critical patent/ATE535252T1/de

Links

208000024827 Alzheimer disease Diseases 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
239000000863 peptide conjugate Substances 0.000 title 1
239000012634 fragment Substances 0.000 abstract 4
230000002163 immunogen Effects 0.000 abstract 4
208000037259 Amyloid Plaque Diseases 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
230000009286 beneficial effect Effects 0.000 abstract 1
210000004556 brain Anatomy 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000003028 elevating effect Effects 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Mycology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT06751930T 2005-05-05 2006-05-01 Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit ATE535252T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US67788605P	2005-05-05	2005-05-05
PCT/US2006/016481 WO2006121656A2 (en)	2005-05-05	2006-05-01	Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease

Publications (1)

Publication Number	Publication Date
ATE535252T1 true ATE535252T1 (de)	2011-12-15

Family

ID=37019042

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06751930T ATE535252T1 (de)	2005-05-05	2006-05-01	Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit

Country Status (16)

Country	Link
US (2)	US7850973B2 (de)
EP (2)	EP1879613B1 (de)
JP (1)	JP2008540417A (de)
KR (1)	KR20080005260A (de)
CN (1)	CN101171031B (de)
AT (1)	ATE535252T1 (de)
AU (1)	AU2006246382A1 (de)
BR (1)	BRPI0610093A2 (de)
CA (1)	CA2607868A1 (de)
IL (1)	IL186793A0 (de)
MX (1)	MX2007013825A (de)
NO (1)	NO20076239L (de)
NZ (1)	NZ562434A (de)
RU (1)	RU2406529C2 (de)
WO (1)	WO2006121656A2 (de)
ZA (1)	ZA200708635B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1838348B1 (de)	2004-12-15	2013-06-26	Janssen Alzheimer Immunotherapy	Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
HRP20140240T4 (hr)	2005-11-30	2017-02-24	Abbvie Inc.	Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
JP2009518010A (ja)	2005-11-30	2009-05-07	アボット・ラボラトリーズ	ヒトβアミロイドタンパク質の組み換え形態の調製方法及びこれらのタンパク質の使用
US8691224B2 (en)	2005-11-30	2014-04-08	Abbvie Inc.	Anti-Aβ globulomer 5F7 antibodies
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en)	2007-02-27	2014-11-25	AbbVie Deutschland GmbH & Co. KG	Method for the treatment of amyloidoses
PE20090329A1 (es) *	2007-05-30	2009-03-27	Abbott Lab	Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
US8048420B2 (en)	2007-06-12	2011-11-01	Ac Immune S.A.	Monoclonal antibody
US8613923B2 (en)	2007-06-12	2013-12-24	Ac Immune S.A.	Monoclonal antibody
NZ581835A (en) *	2007-06-12	2012-09-28	Ac Immune Sa	Monoclonal anti beta amyloid antibody
DK2182983T3 (da)	2007-07-27	2014-07-14	Janssen Alzheimer Immunotherap	Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
EP2020602A1 (de) *	2007-08-02	2009-02-04	Araclon Biotech	Hochempfindliche Immuntests und Kits zur Bestimmung biologisch interessanter Peptide und Proteine
AU2008311367B2 (en)	2007-10-05	2014-11-13	Ac Immune S.A.	Use of anti-amyloid beta antibody in ocular diseases
ITMI20071975A1 (it) *	2007-10-12	2009-04-13	Fond I R C C S Istituto Neur O	Prodotti e loro uso per la diagnosi prevenzione e-o cura di patologie umane e-o animali caraterizzate dalla anomala deposizione di sostanza b-amiloide e-o similamiloide in organi e tesstui umani e-o animali e metodo di screening per la determinazione
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
US8586706B2 (en)	2007-10-25	2013-11-19	Kagoshima University	Peptide vaccine using mimic molecules of amyloid β peptide
CN102112488A (zh) *	2008-07-01	2011-06-29	由卫生福利和体育大臣代表的荷兰王国	抗淀粉样折叠中间体的疫苗
AU2009268808A1 (en) *	2008-07-08	2010-01-14	Merck Sharp & Dohme Corp.	Vaccine for the treatment of Alzheimer's disease
EP2149380A1 (de) *	2008-07-29	2010-02-03	Medivet Pharma, S.L.	Tierärztliche Immuntherapiezusammensetzung für altersbedingte kognitive Dysfunktion
AU2009301631A1 (en) *	2008-10-06	2010-04-15	Commonwealth Scientific And Industrial Research Organisation	Amyloid-beta peptide crystal structure
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
EP2258398A1 (de) *	2009-05-26	2010-12-08	Araclón Biotech, S. L.	Albumin/Amyloidpeptid-Konjugate und deren Verwendungen
CN106390107B (zh) *	2009-06-10	2019-12-31	纽约大学	病理tau蛋白的免疫靶向
US20130084245A1 (en)	2010-02-25	2013-04-04	Wyeth Llc	Pet monitoring of a-beta-directed immunotherapy
US8987419B2 (en)	2010-04-15	2015-03-24	AbbVie Deutschland GmbH & Co. KG	Amyloid-beta binding proteins
EP2598882B1 (de)	2010-07-30	2017-07-26	AC Immune S.A.	Sichere und funktionelle humanisierte antikörper für die verwendung in der behandlung von einer amyloidose
EP3533803B1 (de)	2010-08-14	2021-10-27	AbbVie Inc.	Anti-amyloid-beta antikörper
US20120328605A1 (en) *	2010-10-27	2012-12-27	Daniel Larocque	Compositions and uses
WO2012072611A1 (de) *	2010-11-29	2012-06-07	Philipps-Universität Marburg	SYNTHETISCHE LIGANDEN FÜR HUMANE ANTI-Aβ-ANTIKÖRPER
GB201113570D0 (en) *	2011-08-05	2011-09-21	Glaxosmithkline Biolog Sa	Vaccine
WO2013059322A2 (en) *	2011-10-17	2013-04-25	Lawrence Steinman	Amyloid beta peptide as a therapy for inflammation
KR102730367B1 (ko) *	2014-04-15	2024-11-15	그리피스 유니버시티	그룹 a 스트렙토코쿠스 백신
CN107073297B (zh)	2014-07-08	2021-09-14	纽约大学	Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途
WO2017027685A2 (en)	2015-08-13	2017-02-16	New York University	Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
ES2571055B1 (es) *	2016-02-15	2016-12-28	Araclon Biotech, S.L.	Conjugado amiloide y usos y procedimientos del mismo
CN109072274A (zh) *	2016-04-14	2018-12-21	道健康生活医药株式会社	淀粉样蛋白球体（aspd）样结构体及医药组合物
KR101898623B1 (ko)	2016-11-10	2018-09-13	주식회사 브레인숲	종이 완구블록
CN111201030B (zh)	2017-07-25	2024-11-01	真和制药有限公司	通过阻断tim-3和其配体的相互作用治疗癌症
CN111787942B (zh)	2017-10-25	2024-03-29	杨森制药公司	磷酸化Tau肽的组合物及其用途
RU2679059C1 (ru) *	2018-04-17	2019-02-05	Александр Олегович Морозов	Пептид и способ лечения болезни альцгеймера
RU2679080C1 (ru) *	2018-04-17	2019-02-05	Александр Олегович Морозов	Пептид и способ лечения болезни альцгеймера
WO2020160156A2 (en)	2019-01-30	2020-08-06	Immutics, Inc.	Anti-gal3 antibodies and uses thereof
MY206596A (en)	2019-02-08	2024-12-25	Janssen Pharmaceuticals Inc	Method of safe administration of phosphorylated tau peptide vaccine
EP4157338A4 (de)	2020-05-26	2024-11-13	TrueBinding, Inc.	Verfahren zur behandlung von entzündungskrankheiten durch galectin-3-blockierung
CN116063382B (zh) *	2022-11-17	2024-11-05	山东大学	一种具有三阶非线性光学性能的多肽材料及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5494808A (en)	1994-09-15	1996-02-27	Merck & Co., Inc.	Defined medium OMPC fermentation process
US6905686B1 (en) *	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) *	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
JP3854481B2 (ja) *	2000-11-17	2006-12-06	三菱重工業株式会社	湿式排煙脱硫装置、及び、湿式排煙脱硫方法
WO2003000719A2 (en) *	2001-06-20	2003-01-03	Ramot At Tel Aviv University Ltd.	Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same
MY144532A (en) *	2001-08-20	2011-09-30	Lundbeck & Co As H	Novel method for down-regulation of amyloid
NZ567324A (en) *	2003-02-01	2009-08-28	Wyeth Corp	Active immunization to generate antibodies to soluble A-beta
KR101157694B1 (ko) *	2003-12-17	2012-06-20	와이어쓰 엘엘씨	면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조 방법

2006
- 2006-05-01 EP EP06751930A patent/EP1879613B1/de not_active Expired - Lifetime
- 2006-05-01 JP JP2008510087A patent/JP2008540417A/ja active Pending
- 2006-05-01 MX MX2007013825A patent/MX2007013825A/es active IP Right Grant
- 2006-05-01 EP EP10181823A patent/EP2269633A1/de not_active Withdrawn
- 2006-05-01 US US11/919,897 patent/US7850973B2/en not_active Expired - Fee Related
- 2006-05-01 CA CA002607868A patent/CA2607868A1/en not_active Abandoned
- 2006-05-01 BR BRPI0610093-7A patent/BRPI0610093A2/pt not_active IP Right Cessation
- 2006-05-01 NZ NZ562434A patent/NZ562434A/en not_active IP Right Cessation
- 2006-05-01 CN CN2006800153890A patent/CN101171031B/zh not_active Expired - Fee Related
- 2006-05-01 RU RU2007145052/10A patent/RU2406529C2/ru not_active IP Right Cessation
- 2006-05-01 AT AT06751930T patent/ATE535252T1/de active
- 2006-05-01 KR KR1020077025682A patent/KR20080005260A/ko not_active Ceased
- 2006-05-01 AU AU2006246382A patent/AU2006246382A1/en not_active Abandoned
- 2006-05-01 WO PCT/US2006/016481 patent/WO2006121656A2/en not_active Ceased
2007
- 2007-10-10 ZA ZA2007/08635A patent/ZA200708635B/en unknown
- 2007-10-18 IL IL186793A patent/IL186793A0/en unknown
- 2007-12-04 NO NO20076239A patent/NO20076239L/no not_active Application Discontinuation
2010
- 2010-11-08 US US12/907,493 patent/US20110052611A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ZA200708635B (en)	2008-10-29
CN101171031B (zh)	2011-09-28
AU2006246382A1 (en)	2006-11-16
CA2607868A1 (en)	2006-11-16
MX2007013825A (es)	2008-01-18
EP2269633A1 (de)	2011-01-05
RU2406529C2 (ru)	2010-12-20
IL186793A0 (en)	2008-02-09
US7850973B2 (en)	2010-12-14
JP2008540417A (ja)	2008-11-20
NZ562434A (en)	2010-04-30
EP1879613A2 (de)	2008-01-23
WO2006121656A3 (en)	2007-01-04
EP1879613B1 (de)	2011-11-30
CN101171031A (zh)	2008-04-30
NO20076239L (no)	2008-01-30
BRPI0610093A2 (pt)	2008-12-09
RU2007145052A (ru)	2009-06-10
WO2006121656A2 (en)	2006-11-16
US20090098155A1 (en)	2009-04-16
KR20080005260A (ko)	2008-01-10
US20110052611A1 (en)	2011-03-03

Publication	Publication Date	Title
ATE535252T1 (de)	2011-12-15	Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit
ES2407429T3 (es)	2013-06-12	Vacuna terapéurica
AR024074A1 (es)	2002-09-04	FRAGMENTO ABETA UNIDO A UN PÉPTIDO PORTADOR PARA PREVENIR O TRATAR ENFERMEDADES ASOCIADAS CON DEPoSITOS AMILOIDES DE ABETA, COMPOSICIONES FARMACÉUTICAS QUE LO CONTIENEN, Y SU USO EN LA PREPARACION DE MEDICAMENTOS.
IL164643A (en)	2011-11-30	Peptides, immunogenic compositions containing them and use thereof for the preparation of medicaments for the treatment of alzheimer's disease
MX349481B (es)	2017-07-31	Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
NO20071267L (no)	2007-05-09	Forhindring og behandling av synukleinopatiske og amyloidogene sykdommer
MY158903A (en)	2016-11-30	Antibodies specific for the protofibril form of beta-amyloid protein
MXPA05008156A (es)	2005-09-30	Inmunizacion activa para generar anticuerpos para beta-a soluble.
EA200601761A1 (ru)	2007-06-29	Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения
EA201270144A1 (ru)	2012-07-30	Комбинированная терапия при лечении диабета
RU2009102815A (ru)	2010-08-10	Полипептиды из neisseria meningitidis
EA200701519A1 (ru)	2008-02-28	Живая аттенуированная ротавирусная вакцина для перорального введения
ATE369380T1 (de)	2007-08-15	Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
RU2009148539A (ru)	2011-06-27	Способ лечения болезни альцгеймера
ATE551060T1 (de)	2012-04-15	Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
JP2006506942A5 (de)	2006-04-13
JP2009520758A5 (de)	2010-02-12
MA27699A1 (fr)	2006-01-02	Vaccin contre vhc
JP2017508006A5 (de)	2018-02-22
UA99094C2 (ru)	2012-07-25	Способ лечения пациента с системной красной волчанкой
DE60137146D1 (de)	2009-02-05	Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
WO2005012330A3 (en)	2005-09-09	AMYLOID β-PEPTIDE AND METHODS OF USE
MX2008001520A (es)	2008-04-07	Composiciones de tizanidina y metodos de tratamiento usando las composiciones.
WO2006138745A3 (en)	2007-11-29	Therapeutic peptides and vaccines
CN121001737A (zh)	2025-11-21	Tau和β淀粉样肽免疫原组合物及相关方法